5.3 Renal & Genitourinary Disorders

5.3 Renal & Genitourinary Disorders

Renal and genitourinary disorders account for substantial morbidity and critical care resource utilization across healthcare settings in Abu Dhabi. The DOH Nursing Qualification Examination heavily evaluates clinical judgment regarding Acute Kidney Injury (AKI) etiology and staging, Chronic Kidney Disease (CKD) systemic complications, dialytic modalities (hemodialysis vascular access and peritoneal dialysis peritonitis), and Catheter-Associated Urinary Tract Infection (CAUTI) prevention bundles. Mastery of these concepts is essential to safeguard patients from life-threatening fluid overload, lethal hyperkalemia, and healthcare-associated infections.

---

Acute Kidney Injury (AKI): Staging & Etiological Categories

Acute Kidney Injury is characterized by an abrupt, rapid decline in renal excretory function, resulting in the retention of nitrogenous waste products (urea, creatinine) and failure of extracellular fluid volume and electrolyte homeostasis.

Diagnostic Criteria (KDIGO Framework)

Under the Kidney Disease: Improving Global Outcomes (KDIGO) standardized clinical guidelines, AKI is formally diagnosed by the presence of any one of the following criteria:

• Increase in Serum Creatinine by >=0.3 mg/dL (>=26.5 micromol/L) within 48 hours, OR
• Increase in Serum Creatinine to >=1.5 times baseline, known or presumed to have occurred within the prior 7 days, OR
• Urine Volume <0.5 mL/kg/hr for 6 consecutive hours.

Etiological Classification: Prerenal, Intrarenal & Postrenal

Clinical Phases of Acute Kidney Injury

1. Oliguric Phase:
   • Characterized by daily urine output <400 mL/day (or <0.5 mL/kg/hr in adults), typically lasting 1 to 3 weeks.
   • Pathological Consequences: Intravascular volume overload (hypertension, peripheral edema, jugular venous distension, pulmonary edema), metabolic acidosis (impaired excretion of hydrogen ions and failure to regenerate bicarbonate), severe hyperkalemia, hyperphosphatemia, hypocalcemia, and uremic encephalopathy.
   • Strict Fluid Restriction Formula: Fluid intake must be restricted to the previous 24-hour total measured fluid output (urine + emesis + surgical drainage) PLUS 500 to 600 mL (insensible fluid loss via skin perspiration and respiratory evaporation). Weigh patient daily at the same time using the same scale; 1 kg of acute weight gain equals 1000 mL of retained fluid.
2. Diuretic Phase:
   • Glomerular filtration begins to recover, but regenerating tubular epithelial cells cannot yet concentrate urine or reabsorb solutes. Daily urine output increases dramatically to 1 to 5 liters/day.
   • Major Clinical Hazards: Severe hypovolemic dehydration, hypotension, and life-threatening electrolyte depletion (severe hypokalemia and hyponatremia). Intensive IV fluid and electrolyte replacement guided by frequent laboratory surveillance is essential.
3. Recovery Phase:
   • Glomerular filtration rate increases, and BUN and serum creatinine plateau then steadily decline toward baseline. Full functional tubular recovery takes 3 to 12 months. Some individuals sustain residual renal scarring, progressing to chronic kidney disease.

---

Chronic Kidney Disease (CKD) & End-Stage Renal Disease (ESRD)

Chronic Kidney Disease is defined as kidney damage or a Glomerular Filtration Rate (GFR) <60 mL/min/1.73 m² persisting for >=3 months, regardless of etiology. The primary global and UAE causes are diabetic nephropathy and hypertensive nephrosclerosis.

CKD Staging by Glomerular Filtration Rate (GFR)

• Stage 1: Kidney damage with normal or elevated GFR (>=90 mL/min/1.73 m² with persistent proteinuria/albuminuria).
• Stage 2: Kidney damage with mild GFR reduction (60–89 mL/min/1.73 m²).
• Stage 3a: Mild-to-moderate GFR reduction (45–59 mL/min/1.73 m²).
• Stage 3b: Moderate-to-severe GFR reduction (30–44 mL/min/1.73 m²).
• Stage 4: Severe GFR reduction (15–29 mL/min/1.73 m²; multidisciplinary preparation for renal replacement therapy).
• Stage 5: Kidney failure with GFR<15 mL/min/1.73 m². Plan kidney-replacement options, but initiate dialysis from symptoms, refractory fluid/electrolyte disturbances and the overall clinical assessment rather than this GFR cutoff alone.

Systemic Complications & Evidence-Based Interventions

1. Severe Hyperkalemia Management

As functioning nephrons decline, potassium clearance drops, predisposing patients to fatal cardiac toxicity. PossibleECG findings include peakedT waves, PR prolongation, loss ofP waves, QRS widening, a sine-wave pattern and fatal arrhythmias. They do not follow a reliable sequence, and a normalECG does not exclude severe hyperkalemia.

• STEP 1: CARDIAC MEMBRANE STABILIZATION (Immediate Action):
  • Give the prescribed IV calcium gluconate dose under ECG monitoring, reassessing the need for repeat dosing. Calcium chloride is an alternative with about three times the elemental calcium per equal 10%volume; the preparations are not interchangeable milliliter for milliliter.
  • Mechanism & Rationale: Calcium directly antagonizes the cardiotoxic depolarization effects of high potassium on myocardial conducting tissues, stabilizing cell membrane excitability. It acts within 1 to 3 minutes, lasting 30 to 60 minutes.
  • CRITICAL EXAM POINT: Calcium gluconate DOES NOT lower serum potassium concentrations; it merely prevents fatal ventricular dysrhythmias, buying time for potassium-lowering therapies.
• STEP 2: INTRACELLULAR POTASSIUM SHIFT:
  • Administer 10 units of Regular Insulin IV push accompanied by 50 mL of 50% Dextrose (D50W / 25 g) over 5 minutes. Insulin stimulates the Na+/K+-ATPase pump, shifting potassium rapidly from extracellular fluid into intracellular compartments. Dextrose prevents severe insulin-induced hypoglycemia.
  • Adjunctive therapy: Inhaled Nebulized Albuterol (10 to 20 mg) (stimulates beta-2 receptors to drive potassium into cells) and IV Sodium Bicarbonate (50 mEq) if severe metabolic acidosis is present.
• STEP 3: POTASSIUM ELIMINATION:
  • Prescribed oral potassium binders, such as Sodium Zirconium Cyclosilicate (Lokelma) or Patiromer (Veltassa), can assist potassium removal. They must not delay IV stabilization or urgent dialysis. Patiromer is for oral administration and has a delayed onset; it is not a replacement for emergency treatment.
  • Administer IV Loop Diuretics (furosemide) if residual renal function exists.
  • Hemodialysis: The most definitive, rapid, and effective modality to clear potassium in patients with ESRD or refractory hyperkalemia.

2. Renal Anemia

• Pathophysiology: Loss of functioning renal peritubular capillary interstitial cells results in deficient synthesis of Erythropoietin (EPO), shortening erythrocyte lifespan and causing normochromic, normocytic anemia.
• Treatment Protocol: Administer Erythropoiesis-Stimulating Agents (ESAs), such as Epoetin alfa (Epogen/Procrit) or Darbepoetin alfa (Aranesp) subcutaneously or intravenously.
• ESA Safety and Hemoglobin Target: Use the lowest effective prescribedESA dose. KDIGO 2026 recommends maintaining Hb below 11.5 g/dL in adults treated withESAs; follow product-specific dose limits and monitor Hb/BP. Higher targets increase cardiovascular, stroke and thrombotic risks and are not a goal of therapy.
• Iron Supplementation: Ensure adequate iron stores (transferrin saturation >=20% and serum ferritin >=100–200 ng/mL) before and during ESA therapy. ESA therapy is completely ineffective if iron stores are depleted; IV iron sucrose or oral iron is co-administered.

3. CKD-Mineral and Bone Disorder (CKD-MBD / Renal Osteodystrophy)

• Pathophysiology: Failing nephrons cannot excrete dietary phosphate, producing hyperphosphatemia. High serum phosphate binds ionized calcium, precipitating calcium-phosphate salts in tissues. Concurrently, injured renal tubules fail to convert 25-hydroxyvitamin D into active Calcitriol (1,25-dihydroxyvitamin D3), suppressing intestinal calcium absorption and causing hypocalcemia.
• Persistent hypocalcemia and hyperphosphatemia trigger chronic, excessive secretion of Parathyroid Hormone (Secondary Hyperparathyroidism), which mobilizes calcium out of bones via osteoclastic resorption, causing high-turnover bone disease (osteitis fibrosa), bone pain, pathological fractures, and widespread vascular/valvular calcification.
• Nursing Interventions:
  • Restrict dietary phosphorus (<800 to 1000 mg/day; limit dairy, colas, chocolate, nuts, and processed foods).
  • Administer Oral Phosphate Binders: Calcium-based binders (Calcium Carbonate, Calcium Acetate [PhosLo]) or non-calcium binders (Sevelamer hydrochloride [Renagel], Lanthanum carbonate).
  • CRITICAL ADMINISTRATION RULE: Phosphate binders MUST be taken strictly with meals (during or within 10 to 15 minutes of eating). Phosphate binders act locally within the gastrointestinal tract to bind dietary phosphorus, creating insoluble complexes excreted in feces. If taken on an empty stomach, they fail to bind dietary phosphate and merely act as systemic calcium supplements or cause gastrointestinal irritation.
  • Administer active Calcitriol / Vitamin D analogues to suppress parathyroid hormone once serum phosphorus is controlled.

---

Dialysis Modalities: Hemodialysis vs. Peritoneal Dialysis

Hemodialysis (HD): Access Assessment & Procedural Safeguards

Vascular Access Modalities

• Arteriovenous (AV) Fistula (Gold Standard): Created by surgically anastomosing a native artery directly to a native vein (most commonly radial artery to cephalic vein). Lowest infection and thrombosis rates. Requires 2 to 3 months to mature before cannulation (arterial blood pressure thickens and arterializes the vein wall to withstand high-volume dialysis needles).
• Arteriovenous (AV) Graft: Synthetic polytetrafluoroethylene (PTFE) tube bridging an artery and vein. Maturation requires 2 to 4 weeks; higher incidence of thrombosis and graft infection compared to native fistulas.
• Central Venous Catheter (Double-Lumen): Tunneled or non-tunneled dual-lumen catheter placed in internal jugular vein. Used as a temporary bridge; highest bacteremia risk.

Clinical Vascular Access Assessment

• Auscultation: Auscultate over the access site with a stethoscope to confirm a continuous, low-pitched, blowing or whooshing sound (bruit).
• Palpation: Gently palpate the access site to feel a continuous vibrating or buzzing sensation (thrill).
• Clinical Alert: Absence of a palpable thrill or audible bruit indicates vascular access thrombosis or stenosis. The nurse must notify the nephrologist or vascular access surgeon immediately.

Access Arm Protection Bundle

• NEVER measure blood pressure, perform venipuncture, or start peripheral IV lines in the extremity containing the AV fistula or graft.
• Apply a highly visible "Limb Alert" band to the access arm.
• Educate the patient to avoid wearing tight clothing, wristwatches, or jewelry on the access arm, avoid carrying heavy bags (>5 kg) on that side, and avoid sleeping with the head resting on the access extremity.

Dialysis-Associated Steal Syndrome (DASS)

Arterial steal syndrome occurs when blood is diverted away from the distal capillary bed of the hand through the low-resistance venous outflow of the AV fistula or graft.

• Assessment Findings: The hand distal to the access site appears cold, pale, cyanotic, with diminished or absent radial pulses, delayed capillary refill (>3 seconds), paresthesias, and ischemic rest pain that characteristically worsens during active hemodialysis.
• Action: Report immediately to the surgical team; prolonged distal ischemia causes permanent neuromuscular contractures and ischemic digital gangrene.

Dialysis Disequilibrium Syndrome (DDS)

A rare, life-threatening neurological complication occurring during or immediately following initial or rapid hemodialysis in patients with marked uremia (extremely high baseline BUN levels).

• Pathophysiological Mechanism: Rapid clearance of blood urea lowers intravascular plasma osmolality faster than urea can diffuse across the blood-brain barrier out of brain tissue. The resulting osmotic gradient draws water out of the vascular space into brain parenchyma, precipitating acute cerebral edema and increased intracranial pressure (ICP).
• Clinical Manifestations: Severe throbbing headache, nausea, projectile vomiting, intense restlessness, agitation, confusion, muscle twitching, seizures, and progressive coma.
• Prevention & Nursing Management: For initial dialysis sessions, prescribe short treatment times (<=2 hours) and low blood pump speeds (150–200 mL/min). If symptoms appear, notify the nephrologist immediately, slow or discontinue dialysis, elevate the head of the bed, and administer hypertonic saline (3% NaCl) or IV mannitol as prescribed to increase intravascular osmolality.

Peri-Dialytic Nursing Care

• Check pre-dialysis vital signs, baseline laboratory values, and pre-dialysis weight.
• Calculate fluid to be removed: Pre-dialysis Weight - Patient's Target Dry Weight = Volume to ultrafilter.
• Medication Timing: Review the prescribed dialysis-day plan. Antihypertensive timing depends on BP control and intradialytic hypotension; do not automatically omit every BP medicine. Give dialyzable medicines at the prescribed time, often after dialysis or with an ordered replacement dose, after checking the drug-specific plan.

---

Peritoneal Dialysis (PD): Mechanics & Complications

Peritoneal dialysis utilizes the patient's rich peritoneal capillary bed as a semipermeable membrane across which fluid and solutes diffuse into hypertonic dialysate instilled into the peritoneal cavity.

Three-Phase Exchange Cycle

1. Inflow (Fill): Instill 1.5 to 2.5 L of sterile, pre-warmed dialysate (containing 1.5%, 2.5%, or 4.25% dextrose) into the peritoneal cavity via gravity over approximately 10 minutes.
2. Dwell: Dialysate remains inside the abdomen for the prescribed time (4 to 8 hours in Continuous Ambulatory Peritoneal Dialysis [CAPD], or shorter cycles overnight in Automated Peritoneal Dialysis [APD]). Hypertonic dextrose creates an osmotic gradient that extracts excess fluid (ultrafiltration) and metabolic wastes.
3. Drain (Outflow): Fluid drains out by gravity into a collection bag over 20 to 30 minutes.

Peritonitis Recognition and Management

Peritonitis is the most frequent and serious complication of peritoneal dialysis, typically introduced by touch contamination during catheter connection.

• Cardinal Clinical Sign: Cloudy or turbid dialysate effluent is the earliest, most sensitive indicator of peritonitis (normal effluent is completely clear and straw-yellow).
• Other symptoms: Diffuse abdominal pain, rebound tenderness, fever, chills, nausea, and malaise.
• Priority Nursing Actions:
  1. Immediately send the cloudy dialysate effluent bag to the laboratory for cell count, differential, Gram stain, and bacterial culture (peritonitis is confirmed by dialysate WBC >100/mcL with >50% polymorphonuclear neutrophils).
  2. Notify the nephrologist immediately.
  3. Administer Intraperitoneal (IP) Antibiotics (broad-spectrum covering Gram-positive and Gram-negative organisms, such as cefazolin and ceftazidime or aminoglycoside) added directly into dialysate bags.
  4. Reiterate strict aseptic technique, including mandatory face mask wear by both patient and nurse during all transfer-set connections.

Dialysate Inflow/Outflow Troubleshooting

If dialysate outflow is sluggish or volume is less than infused:

• Check tubing for mechanical obstructions, kinks, closed clamps, or air locks.
• Reposition the Patient: Turn the patient from side to side, elevate the head of the bed, or have the patient ambulate to redistribute fluid over catheter fenestrations.
• Ensure the drainage collection bag is placed below the level of the patient's abdomen to maximize gravity siphon drainage.
• Assess Bowel Function: Constipation / fecal impaction is the most common cause of catheter outflow failure (a distended, stool-filled colon compresses the catheter against the pelvic wall); administer prescribed stool softeners or enemas.
• CRITICAL SAFETY RULE: Never push, manipulate, or forcefully advance the peritoneal dialysis catheter.

---

Comparison: Hemodialysis vs. Peritoneal Dialysis

---

Indwelling Urinary Catheter Care & CAUTI Prevention Bundle

Catheter-Associated Urinary Tract Infections (CAUTIs) represent one of the most prevalent healthcare-associated infections worldwide. Implementing evidence-based catheter insertion and maintenance bundles is a statutory quality priority under Department of Health Abu Dhabi standards.

Clinical Indications for Indwelling Catheter Placement

Catheters must be placed only for documented, evidence-based indications:

• Acute urinary retention or mechanical bladder outlet obstruction.
• Accurate hourly urinary output measurement in critically ill, hemodynamically unstable patients.
• Perioperative use for specific urological, gynecological, or prolonged surgical procedures.
• Assistance in healing open sacral or perineal Stage 3 or 4 pressure injuries in incontinent patients.
• Patient requiring strict prolonged immobilization (unstable thoracic/lumbar spine fractures, multiple pelvic fractures).
• Palliative and comfort care in terminally ill patients.

Evidence-Based CAUTI Prevention Protocol

1. Aseptic Insertion Technique:
   • Perform rigorous hand hygiene before and after insertion.
   • Utilize a sterile catheter kit containing sterile gloves, fenestrated drape, antiseptic cleansing swabs, and sterile lubricant.
   • Maintain strict aseptic technique throughout the procedure; if the catheter touches non-sterile surfaces (or enters the vagina in females), discard it and restart with a fresh sterile catheter kit.
2. Catheter Securement:
   • Secure the catheter tubing to the patient's upper thigh (females) or lower abdomen / upper anterolateral thigh (males) using a commercial catheter securement device (e.g., StatLock).
   • Rationale: Anchoring prevents catheter movement, urethral traction, meatal erosion, bladder neck trauma, and accidental balloon displacement.
3. Closed Drainage System Integrity:
   • Maintain a continuously closed drainage system. Never disconnect the catheter-to-drainage tubing junction unless strictly necessary for sterile continuous bladder irrigation.
   • Obtain urine specimens aseptically through the needleless sampling port after scrubbing the port vigorously with 70% alcohol; never disconnect the tubing to collect specimens.
4. Dependent Gravity Drainage:
   • Position the urinary collection bag continuously below the level of the bladder at all times to prevent gravitational backflow of stagnant, colonized urine into the bladder.
   • Secure the collection bag to the bed frame; never hang the bag on the bed side rail (elevating the rail raises the bag above bladder level) and never place the bag on the floor (risks gross bacterial contamination of the drainage spout).
   • Ensure tubing remains straight and free of dependent loops, kinking, or compression.
5. Routine Meatal Hygiene:
   • Clean the urethral meatus and proximal catheter tubing daily and after each bowel movement using mild soap and water.
   • Avoid routine application of povidone-iodine, chlorhexidine, or antimicrobial ointments to the urethral meatus, as chemical irritation disrupts normal periurethral flora and promotes resistant bacterial colonization.
6. Emptying the Drainage Bag:
   • Empty the collection bag when it is 2/3 full or at least once per shift using a clean, dedicated measuring container for each patient.
   • Prevent contact between the drainage spigot and the non-sterile collection vessel.
7. Daily Necessity Review & Prompt Removal (Nurse-Driven Bundle):
   • The daily risk of developing bacteriuria increases by 3% to 7% for each day an indwelling catheter remains in place.
   • Conduct a daily multidisciplinary review of catheter necessity; utilize nurse-driven removal protocols to discontinue the catheter immediately once the clinical indication ceases.